TickerTalks
Browse all tickers →
TickerTalks›$NTHI
NTNTHI

Neonc Technologies Holdings, Inc.

Hot onWhy it's trendingX mentions rising faster than the marketMoving on elevated volume
$NTHI·$113M·Biotechnology·Healthcare
$4.22+31.5%1Y-18.7%
Mentions · last 7 days
2026-08-07: 0 posts2026-08-08: 0 posts2026-08-09: 1 posts2026-08-10: 16 posts2026-08-11: 11 posts2026-08-12: 33 posts2026-08-13: 5 posts66+110%
Price updated 5h ago·X counts updated 1d ago
NTNTHI
$NTHINeonc Technologies Holdings, Inc.
$4.22+31.46%66 posts+110%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NTHI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-13

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

NeOnc dropped 20% on Q2 despite positive NEO100 Phase 2a data — the data is real; the tape is not yet convinced

NeOnc Technologies is a clinical-stage biotech with an intranasal drug-delivery platform (NEO100) targeting IDH1-mutant high-grade glioma — Q2 data was positive but the equity fell 20% anyway.

  • Q1 EPS -$0.38 vs -$0.22 estimate — 74% miss on loss line; pre-revenue, cash-burn story.
  • NEO100 Phase 2a topline in IDH1-mutant recurrent high-grade glioma beat historical benchmark by ~2.5x (Aug 12) — genuinely encouraging.
  • Stock -20.5% today despite the positive data — either a sell-the-news setup or capital-raise pressure.
  • Tiny 5.7M float with 11x volume multiplier and 19% of float traded — squeeze-mechanics dominated day.
  • Position 4.5% of 52-week range and -50% below 200-day MA — deep capitulation before today's move.

Upside is Phase 2b or partnered validation of NEO100 mechanism; downside is dilutive capital raise or a competitor with better data.

What to watch: Q2 earnings (Aug 14) — cash runway, NEO100 Phase 3 plans, and any partnership commentary.

On the calendar: 2026-08-14

no x samplethin floatcapitulation tape

Read the AI verdict + X sentiment for $NTHI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing targeted molecular delivery therapies for central nervous system cancers and diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NTHI.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
259%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-19.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
284%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 18, 2026$-0.38$-0.22-73.5%
Q4 2025Mar 31, 2026$-0.40$-0.37-7.3%
Q3 2025Nov 14, 2025$-0.45$-0.37-21.6%
Q2 2025Aug 18, 2025$-0.30——
Next earningsFri, Aug 14·consensus EPS $-0.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0-100.0%——$-0.38$-7.0M
Q4 FY25$0———$-0.81$-3.6M
Q3 FY25$0———$-0.45$-5.8M
Q2 FY25$0———$-0.30$-5.3M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$40K$40K – $40K-$0.70-$0.96 – -$0.544
FY27$40K$40K – $40K-$0.62-$0.84 – -$0.404
FY28$40K$40K – $40K-$0.67-$0.67 – -$0.672
FY29$65.0M$65.0M – $65.0M$0.58$0.58 – $0.581
FY30$100.1M$100.1M – $100.1M$0.90$0.90 – $0.901

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.11.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.5%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-50.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 5.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today19.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 128-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on August 13, 2026 (event date August 12) under Item 7.01 (Regulation FD), furnishing a public investor communication concurrently with its Q2 2026 earnings disclosure. The excerpt is the cover page; the actual investor materials are in the attached exhibit. NeOnc Technologies is a clinical-stage oncology company developing intranasal drug delivery therapies for brain cancer. This Reg FD filing is typically an investor presentation or conference slide deck.

8-KPress release / Reg FDAug 108-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on August 11, 2026 under Items 2.02 and 7.01, reporting Q2 2026 financial results and furnishing concurrent Regulation FD investor materials. Body unavailable — earnings details are in Exhibit 99.1, which is not included in the excerpt. NeOnc Technologies is a clinical-stage oncology company developing intranasal drug delivery therapies for brain tumors. The Reg FD filing covers an investor presentation distributed simultaneously with the earnings disclosure.

8-KPress release / Reg FDJul 158-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on July 16, 2026 (event date July 15) under Item 7.01 (Regulation FD), furnishing investor materials publicly. The excerpt is the cover page; the actual materials are in the exhibit. NeOnc is a clinical-stage oncology company. This is one of multiple Reg FD 8-Ks NTHI filed over several months (June–August 2026), reflecting regular investor conference participation or business updates.

3New insider — initial holdingsJul 133
AI summary

Nasim Shomali filed a Form 3 on July 14, 2026 (event date July 1), reporting initial beneficial ownership of 160 shares of NeOnc Technologies (NTHI) directly held upon joining as a Director. The 160-share initial ownership is an unusually small grant, possibly representing a qualifying purchase. NeOnc Technologies is a clinical-stage brain cancer drug delivery company. Future equity grants or purchases will be disclosed on Form 4.

8-KOfficer or director changeJul 28-K — Item 5.02: Officer or director change
AI summary

NeOnc Technologies (NTHI) filed an 8-K on July 3, 2026 (event date June 27) under Item 5.02, reporting a change in its officers or directors. The excerpt is the cover page; the specific officer departure or appointment and circumstances are in the body. NeOnc is a small clinical-stage oncology company focused on intranasal drug delivery for brain tumors. Officer changes at clinical-stage biotechs are monitored for signals of strategic direction or pipeline prioritization shifts.

8-KPress release / Reg FDJun 238-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on June 24, 2026 (event date June 23) under Item 7.01 (Regulation FD), furnishing investor materials publicly. The excerpt is the cover page; the actual materials are in the exhibit. This is one of multiple NTHI Reg FD 8-Ks filed between June and August 2026, reflecting the company's active investor outreach during a period that includes its PIPE financing and S-3 shelf registration.

424B5Prospectus supplement (offering)Jun 23424B5
AI summary

NeOnc Technologies (NTHI) filed a 424B5 prospectus supplement on June 24, 2026, registering the resale of 555,554 shares: 277,777 shares of common stock and 277,777 shares underlying warrants issued in a PIPE transaction on April 20, 2026. This is a selling stockholder resale prospectus — no new proceeds flow to the company; existing PIPE investors are registering their shares for public resale. The offering represents no additional dilution beyond the April PIPE. NeOnc Technologies is a clinical-stage brain cancer drug delivery company.

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

NeOnc Technologies (NTHI) filed an 8-K on June 19, 2026 (event date June 16) under Item 7.01 (Regulation FD), furnishing investor materials publicly. The excerpt is the cover page; the actual materials are in the exhibit. This is one of multiple NTHI Reg FD filings between June and August 2026 as the company actively engages investors during its PIPE financing and clinical program development period.

+ 34 other (11 8-Ks · 3 EFFECTs · 3 S-3s · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26newsfilecorp.com·1d agoThe Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotechglobenewswire.com·1d agoTargeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancerglobenewswire.com·3d agoNeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5xnewsfilecorp.com·3d agoNeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Gliomaglobenewswire.com·3d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport